Your browser doesn't support javascript.
loading
Lifetime Prevalence of Cervical Cancer Screening in 55 Low- and Middle-Income Countries.
Lemp, Julia M; De Neve, Jan-Walter; Bussmann, Hermann; Chen, Simiao; Manne-Goehler, Jennifer; Theilmann, Michaela; Marcus, Maja-Emilia; Ebert, Cara; Probst, Charlotte; Tsabedze-Sibanyoni, Lindiwe; Sturua, Lela; Kibachio, Joseph M; Moghaddam, Sahar Saeedi; Martins, Joao S; Houinato, Dismand; Houehanou, Corine; Gurung, Mongal S; Gathecha, Gladwell; Farzadfar, Farshad; Dryden-Peterson, Scott; Davies, Justine I; Atun, Rifat; Vollmer, Sebastian; Bärnighausen, Till; Geldsetzer, Pascal.
Affiliation
  • Lemp JM; Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany.
  • De Neve JW; Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany.
  • Bussmann H; Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Chen S; Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany.
  • Manne-Goehler J; Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing.
  • Theilmann M; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Marcus ME; Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston.
  • Ebert C; Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany.
  • Probst C; Department of Economics and Centre for Modern Indian Studies, University of Goettingen, Göttingen, Germany.
  • Tsabedze-Sibanyoni L; RWI-Leibniz Institute for Economic Research, Essen (Berlin office), Germany.
  • Sturua L; Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany.
  • Kibachio JM; Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
  • Moghaddam SS; Eswatini Ministry of Health, Mbabane, Eswatini.
  • Martins JS; Non-Communicable Disease Department, National Center for Disease Control and Public Health, Tbilisi, Georgia.
  • Houinato D; Division of Non-Communicable Diseases, Kenya Ministry of Health, Nairobi, Kenya.
  • Houehanou C; Institute of Global Health, Faculty of Medicine, University of Geneva (UNIGE), Geneva, Switzerland.
  • Gurung MS; Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Gathecha G; Faculty of Medicine and Health Sciences, Universidade Nacional Timor Lorosa'e, Rua Jacinto Candido, Dili, Timor-Leste.
  • Farzadfar F; Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.
  • Dryden-Peterson S; Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.
  • Davies JI; Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan.
  • Atun R; Division of Non-Communicable Diseases, Kenya Ministry of Health, Nairobi, Kenya.
  • Vollmer S; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Bärnighausen T; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Geldsetzer P; Botswana Harvard AIDS Institute, Gaborone, Botswana.
JAMA ; 324(15): 1532-1542, 2020 10 20.
Article in En | MEDLINE | ID: mdl-33079153
Importance: The World Health Organization is developing a global strategy to eliminate cervical cancer, with goals for screening prevalence among women aged 30 through 49 years. However, evidence on prevalence levels of cervical cancer screening in low- and middle-income countries (LMICs) is sparse. Objective: To determine lifetime cervical cancer screening prevalence in LMICs and its variation across and within world regions and countries. Design, Setting, and Participants: Analysis of cross-sectional nationally representative household surveys carried out in 55 LMICs from 2005 through 2018. The median response rate across surveys was 93.8% (range, 64.0%-99.3%). The population-based sample consisted of 1 136 289 women aged 15 years or older, of whom 6885 (0.6%) had missing information for the survey question on cervical cancer screening. Exposures: World region, country; countries' economic, social, and health system characteristics; and individuals' sociodemographic characteristics. Main Outcomes and Measures: Self-report of having ever had a screening test for cervical cancer. Results: Of the 1 129 404 women included in the analysis, 542 475 were aged 30 through 49 years. A country-level median of 43.6% (interquartile range [IQR], 13.9%-77.3%; range, 0.3%-97.4%) of women aged 30 through 49 years self-reported to have ever been screened, with countries in Latin America and the Caribbean having the highest prevalence (country-level median, 84.6%; IQR, 65.7%-91.1%; range, 11.7%-97.4%) and those in sub-Saharan Africa the lowest prevalence (country-level median, 16.9%; IQR, 3.7%-31.0%; range, 0.9%-50.8%). There was large variation in the self-reported lifetime prevalence of cervical cancer screening among countries within regions and among countries with similar levels of per capita gross domestic product and total health expenditure. Within countries, women who lived in rural areas, had low educational attainment, or had low household wealth were generally least likely to self-report ever having been screened. Conclusions and Relevance: In this cross-sectional study of data collected in 55 low- and middle-income countries from 2005 through 2018, there was wide variation between countries in the self-reported lifetime prevalence of cervical cancer screening. However, the median prevalence was only 44%, supporting the need to increase the rate of screening.
Subject(s)

Full text: 1 Collection: 01-internacional Health context: 10_ODS3_salud_sexual_reprodutiva / 2_ODS3 Database: MEDLINE Main subject: Patient Acceptance of Health Care / Uterine Cervical Neoplasms / Early Detection of Cancer Type of study: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies / Screening_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: JAMA Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Health context: 10_ODS3_salud_sexual_reprodutiva / 2_ODS3 Database: MEDLINE Main subject: Patient Acceptance of Health Care / Uterine Cervical Neoplasms / Early Detection of Cancer Type of study: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies / Screening_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: JAMA Year: 2020 Document type: Article